The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a monthlong truce.Marketsread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
Credit Suisse analysts Monday initiated shares of Allergan at an "outperform" rating, saying the drugmaker's diversified drug pipeline is "underappreciated" by investors.
"We see it as a company with a broad and underappreciated pipeline that will help boost their already strong base business and that is trading at a compelling valuation and being led by a best-in-class management team," said analyst Vamil Divan in the report.
Last November, Allergan outlined its new "Open Science" research and development model, which is a three-part discovery, development and commercialization process for new drugs. The goal was to help build therapy area leadership and drive long-term growth, according to the company.
At that time, Allergan called out a pipeline that included more than 70 mid-to-late stage development programs. The company also said it planned to focus itself in the following areas: gastroenterology, mental health, women's health and urology, anti-infectives, medical aesthetics and dermatology, neuromodulators and eye care.
Divan said he is "bullish" about its recently launched products such as Vraylar, Viberzi and Kybella, and he expects strong growth for Allergan's existing products such as Botox, Linzess and its medical aesthetics business.
Divan also sees significant drug opportunities such as Abicipar and Rapastinel, though "it will take some time for these to play out."
Among the risks Allergan faces is its $40 billion-plus pending deal with Teva. The sale of Allergan's generics unit has taken longer than expected to close, but Divan expects it will.
Shares of Allergan ended the day down slightly at $247.85. Allergan's stock has plummeted this year, falling more than 20 percent. Credit Suisse set a target price to $327.
AGN 2016 Chart
DISCLOSURE: Credit Suisse does and seeks to do business with companies covered in its research reports.